Effects Of Korea's New Drug-Pricing System Still Murky
This article was originally published in The Pink Sheet Daily
Executive Summary
Local companies and multinational corporations will engage in "bloody battles" to offer the lowest bidding prices to the large nationwide hospitals, one analyst predicts.
You may also be interested in...
New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies
SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices
Korean Government Announces Joint Fund To Beef Up Local Pharma Industry
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.